IR-MED

Company Overview

Snapshot

Founded in September 2012, IR-MED has 11–50 employees and was co-founded by Ronnie Klein. The company has raised $8.73 million across 5 funding rounds from 1 investor. In December 2020, IR-MED completed a reverse merger and a $2.2 million private placement, leading to its public listing on OTCQB.

Business overview

IR-MED develops a non-invasive infrared spectroscopy and AI analysis technology platform for point-of-care decision support devices. This technology gathers bio-information from patient blood and tissue, which is then analyzed using AI to assist healthcare professionals in detecting and monitoring various disease conditions. Its primary product, PressureSafe, is a handheld device designed for the early detection of pressure injuries, aiming to provide equitable healthcare regardless of patient skin tone. The company operates in the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Diagnostics Devices, and serves healthcare providers in markets such as the United States, Europe, and Israel.

Strategic signal

In May 2024, IR-MED's PressureSafe device demonstrated a 50% reduction in pressure injuries during a usability study with Clalit, Israel’s largest HMO. This significant clinical validation, also reported by Medical Device Network, signals strong potential for the device to address a substantial healthcare burden and indicates a positive trajectory for the company's flagship product ahead of its anticipated U.S. launch.

Company Intelligence Q&A

What is IR-MED's primary product?

IR-MED's primary product is PressureSafe, a handheld device that utilizes infrared spectroscopy and AI to non-invasively detect pressure injuries in their early stages, aiming to improve patient outcomes and reduce healthcare costs.

When did IR-MED go public?

IR-MED went public on OTCQB in December 2020, following the completion of a reverse merger and a $2.2 million private placement.

What was a significant recent clinical achievement for PressureSafe?

In May 2024, IR-MED's PressureSafe device reduced pressure injuries by 50% during a usability study conducted with Clalit, Israel’s largest HMO.

Has IR-MED received any grants recently?

In May 2025, IR-MED was awarded a grant from the Israel Innovation Authority to advance its AI-powered DiaSafe device for diabetic foot ulcer assessment. Additionally, in July 2024, the company received a $500,000 grant from the Israel Innovation Authority to develop its platform technology for the early detection of diabetic foot ulcers.

What is the status of IR-MED's DiaSafe device?

In November 2025, IR-MED Ltd. announced the launch of the first-in-human clinical trial for its DiaSafe device, which is designed for Diabetic Foot Ulcer (DFU) assessment.